U.S. Stock News

Gilead Sciences (NasdaqGS:GILD) has expanded its oncology pipeline through a new licensing deal with Repare Therapeutics. Phase 3 data for Trodelvy combined with Merck's Keytruda in first line metastatic triple negative breast cancer were published in The New England Journal of Medicine. These updates highlight oncology as an increasingly important area within Gilead's broader portfolio. For you as an investor, the story at Gilead is increasingly about oncology rather than only virology and...

United Therapeutics recently reported positive phase 1 results for miroliverELAP, an investigational external liver assist device tested in five acute liver failure patients who were not transplant candidates, with survival achieved during treatment and no unexpected serious adverse events over 32 days of follow-up. This early success underscores the company’s broader push into bioengineered organ alternatives, potentially expanding its role beyond pulmonary disease into life-support...

Vishay Intertechnology (VSH) has rolled out a series of new silicon carbide MOSFET power modules and Trench MOS Barrier Schottky rectifier modules, targeting higher efficiency in automotive, energy, industrial, and telecom power systems. See our latest analysis for Vishay Intertechnology. The recent product launches have arrived alongside a sharp shift in sentiment, with Vishay Intertechnology’s 30 day share price return of 35.19% and 1 year total shareholder return of 30.51% contrasting with...

If you are wondering whether Legend Biotech's current share price still reflects its potential, you are not alone. Many investors are asking the same question after a tough period for the stock. Legend Biotech's share price closed at US$17.15, with returns of a 9.5% decline over 7 days, a 20.3% decline over 30 days, a 20.3% decline year to date, a 54.0% decline over 1 year and a 65.5% decline over 3 years. This performance has reshaped how some investors view both its upside and its...

Republic Bancorp (RBCA.A) has come into focus after its Q4 2025 report, which combined higher revenue and net interest income with an adjusted EPS miss and increased net charge-offs, giving investors a mixed earnings picture. See our latest analysis for Republic Bancorp. The share price has moved to US$73.42, with a 1-day share price return of 1.12% and a 90-day share price return of 12.42%. The 1-year total shareholder return of 17.51% and 5-year total shareholder return of 104.74% point to...

Arrowhead Pharmaceuticals (ARWR) has begun dosing participants in a Phase 1/2a trial of ARO DIMER PA, a dual gene targeting RNAi candidate for mixed hyperlipidemia related atherosclerotic cardiovascular disease. See our latest analysis for Arrowhead Pharmaceuticals. The ARO DIMER PA dosing update comes after a strong run in Arrowhead Pharmaceuticals' shares, with a 90 day share price return of 92.87% and a 1 year total shareholder return of 289.54%. Momentum has been building recently,...

Why Cooper Companies is back in focus Cooper Companies (COO) is back on investors’ radar after renewed analyst coverage at William Blair following activist investor pressure, alongside a company review of a potential separation of its CooperVision and CooperSurgical businesses. See our latest analysis for Cooper Companies. Cooper Companies’ share price has been relatively muted in the short term, with a 90 day share price return of 16.75% contrasting with a 1 year total shareholder return...

Sonoco Products (NYSE:SON) has entered a 15 year Virtual Power Purchase Agreement with ENGIE North America to source renewable wind energy. The agreement is intended to support Sonoco's emissions reduction efforts and shift more of its operational energy use toward renewables. The company also announced the planned retirement of Chief Operating Officer Rodger Fuller, alongside an upcoming executive restructuring. For investors watching NYSE:SON, these updates arrive with the share price at...

If you are wondering whether OUTFRONT Media is still reasonably priced after its recent run, this article walks through what the current share price could imply about value. The stock last closed at US$25.23, with returns of 3.2% over 7 days, 6.4% over 30 days, 6.4% year to date, 47.5% over 1 year, 53.3% over 3 years, and 58.1% over 5 years. Those moves sit against a backdrop of ongoing interest in the company as an outdoor advertising REIT and continuing coverage in the financial press that...

In late January 2026, multiple research firms including Truist Financial and H.C. Wainwright reaffirmed positive views on Nuvation Bio after its Ibtrozi cancer franchise showed robust initial uptake despite seasonal headwinds. Analysts also highlighted the company’s mIDH1 glioma program, with key clinical readouts expected as early as 2026, adding another potential growth pillar to its oncology story. We’ll now look at how analyst enthusiasm around Ibtrozi’s early positioning as a preferred...

Recent performance snapshot for Duolingo (DUOL) With no single headline event dominating attention, Duolingo (DUOL) has been drawing interest largely because of its recent share performance and fundamentals, prompting investors to reassess what the current price might already be reflecting. See our latest analysis for Duolingo. At a share price of $131.93, Duolingo’s recent 30 day share price return of a 25.24% decline and 90 day share price return of a 49.65% decline point to fading...

In recent months, Spotify has raised its US premium subscription price from US$11.99 to US$12.99 per month while reporting better‑than‑expected third‑quarter 2025 revenue, gross margin, and operating income amid growing engagement with video podcasts. The company’s push beyond music into podcasts and other high‑engagement formats, combined with analyst optimism about pricing power, is reshaping how investors view its long‑term role in global audio streaming. We’ll examine how Spotify’s...

Weyerhaeuser (NYSE:WY) has announced an increase to its base dividend alongside a new share repurchase program. The company plans significant divestitures of non core timberlands as part of a portfolio reshaping effort. Management has outlined a long term growth strategy targeting higher EBITDA by 2030. For investors watching NYSE:WY, these decisions come as the stock trades around $25.84, with a 30 day return of 8.6% and a 1 year return showing a decline of 13.2%. Over 3 and 5 years, the...

This article is designed to help you think about whether USA Rare Earth is starting to look like good value after a strong run, or whether the current price already reflects the story. USA Rare Earth shares closed at US$22.11, with a 30 day return of 56.3%, a 7 day return showing a 16.1% decline, and a 1 year return of 74.1%, indicating that the stock has seen sharp moves recently. Recent attention on USA Rare Earth has focused on its role in the US rare earth supply chain and the broader...

Recent analyst revisions have turned more cautious on AptarGroup (ATR). Consensus EPS expectations have moved lower despite higher projected revenues, putting margins and costs at the center of the earnings debate. See our latest analysis for AptarGroup. AptarGroup shares recently traded at $124.83, with a 90 day share price return of 9.33% contrasting with a 1 year total shareholder return decline of 18.98%. This suggests recent momentum has improved even as longer term returns remain under...

Smithfield Foods (SFD) is back on investor screens after recent share price moves, with the stock returning 9.3% over the past month and 16.0% over the past 3 months. See our latest analysis for Smithfield Foods. That recent 9.3% 1 month share price return sits alongside a 9.9% 3 month share price return and a 16.0% 1 year total shareholder return. Together, these figures point to momentum building rather than fading around the current US$24.20 level. If Smithfield Foods has caught your eye,...

Bitmine Immersion Technologies (NYSEAM:BMNR) is carrying major unrealized losses on more than 4.24 million ETH, currently estimated at over $6b. The company continues its large scale Ethereum accumulation and treasury approach despite the crypto downturn. President Erik Nelson is departing, with separation terms disclosed as Bitmine prepares for a leadership transition. The company is also moving ahead with plans for a validator network launch tied to its staking and DeFi initiatives. For...

In late January 2026, AppFolio reported its fourth-quarter and full-year 2025 results, with revenue rising to US$248.19 million for Q4 and US$950.82 million for the year, alongside lower net income and earnings per share versus 2024. The company also issued 2026 guidance calling for full-year revenue of US$1.10 billion to US$1.12 billion, highlighting expectations tied to its AI-native performance platform and premium tier adoption. With the company now guiding 2026 revenue to US$1.10–1.12...

SentinelOne recently confirmed that Barry Padgett, previously its Chief Growth Officer, became interim Chief Financial Officer and principal financial officer on January 16, 2026, following the mid-January departure of former CFO Barbara Larson. At the same time, investors are weighing insider share purchases and new partnerships against concerns raised by analysts about SentinelOne’s future revenue trajectory. We’ll now examine how the CFO transition, alongside analyst concerns about future...

SouthState Bank (NYSE:SSB) has approved a new share repurchase program following the completion of its prior buyback. The company has reported full year results that show income growth for the period. Management has affirmed the dividend alongside these capital return decisions. SouthState Bank, a regional banking group serving customers across the Southeast, is updating shareholders on how it is using its balance sheet after its latest results. The combination of a fresh buyback...

If you are wondering whether Macy's current share price still offers value, you are not alone. This article focuses squarely on what the numbers say about the stock. Macy's most recent close was US$21.19, with returns of 4.6% over the past 7 days, a 6.9% decline over 30 days, a 6.9% decline year to date, a 45.9% return over 1 year and a 62.4% return over 5 years. Recent headlines around Macy's have centered on corporate interest in the company and how management might respond, which has put...

Conagra Brands (NYSE:CAG) is launching Banquet MEGA Breakfast Bowls, a new line of frozen breakfast meals. The bowls feature high-protein recipes and use a steaming technology intended to affect texture and taste. The launch adds to Conagra's presence in the frozen breakfast and value focused meal category. For you as an investor, this move sits at the intersection of two themes in packaged foods: demand for protein rich meals and interest in convenient, heat and eat formats. Conagra...

Credo Technology Group Holding (NasdaqGS:CRDO) introduced its Blue Heron 224G AI scale-up retimer, targeting high bandwidth connectivity challenges in AI-scale infrastructure. The company entered a patent licensing agreement with 3M, expanding access to key intellectual property linked to high speed data solutions. Recent reports highlight Credo’s growing role in AI cluster connectivity through telemetry and optimization technologies that support large scale compute networks. Credo, a data...

FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy. The decision allows Intellia to resume late stage development of its gene editing therapy, nexiguran ziclumeran. Regulators addressed prior safety concerns, clearing a key hurdle for this pivotal study. NasdaqGM:NTLA is back in focus after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial, putting nexiguran ziclumeran firmly back on the...